Gilead Sciences
Pfizer Faces Backlash for Raising Price of Covid Drug Paxlovid
Following Pfizer’s announcement to increase the cost of its COVID-19 treatment drug, Paxlovid, for the next year, the AIDS Healthcare ...
Gilead strikes $100 million deal with Assembly Bio for antiviral assets
Gilead Sciences is taking a unique approach to secure early access to Assembly Biosciences’ promising programs. Instead of an outright ...
Magrolimab fails to improve survival in leukemia, Gilead halts trial
Another failure has occurred in Gilead Sciences’ $4.9 billion immuno-oncology wager. Following an ad hoc analysis of a phase 3 ...
Gilead Sciences Proceeds with $247 Million Settlement in HIV Antitrust Case Following Trial Victory
Despite Gilead Sciences and Teva Pharmaceutical Industries emerging victorious in a high-stakes antitrust trial related to HIV drugs earlier this ...
AstraZeneca and Daiichi Reach Key Milestone in Breast Cancer ADC Trial, Paving Way to Challenge Gilead
AstraZeneca and Daiichi Sankyo are making a strategic move to challenge Gilead Sciences’ position in the breast cancer arena. They ...
Lyndra Therapeutics slashes staff and moves HQ ahead of pivotal data for weekly oral schizophrenia pill
Lyndra Therapeutics is undergoing significant changes, including the appointment of Jessica Ballinger as its new CEO, following the replacement of ...
Gilead’s $100M COMPASS Initiative Shifts Course of the HIV Epidemic
Gilead Sciences is pausing to reflect on its $100 million commitment to combat the HIV/AIDS crisis in the southern United ...
Gilead’s Magrolimab Faces Fresh Setback as FDA Issues Partial Clinical Hold
One month after Gilead Sciences made public its decision to halt a myelodysplastic syndromes (MDS) program centered around magrolimab, the ...
A2R, a prostate cancer medication, is discontinued by Arcus and Gilead
Arcus and Gilead Sciences have opted to discontinue the development of their A2 receptor antagonist, etrumadenant, for castration-resistant prostate cancer ...
Gileadās $3B Oncology Milestone: Trodelvy, Tecartus and Yescarta Lead the Way in 2023
Gilead Sciences has been making significant strides in the oncology space, fueled by the success of its rising star drug, ...
Gilead’s Trodelvy for Pre-Treated HR+/HER2- Metastatic Breast Cancer Receives European Commission Approval
Source – Gilead Gilead Sciences, has received approval from the European Commission (EC) for the use of Trodelvy (sacituzumab govitecan) ...
Magrolimab for myelodysplastic syndromes is discontinued by Gilead
Source – Gilead Science Gilead Sciences has announced the discontinuation of its cancer antibody, magrolimab, in the treatment of blood ...
Twice-Yearly Lenacapavir Boosts HIV Patients’ Quality of Life
Source – Gilead Gilead Sciences presented new data at the 12th International AIDS Society (IAS) Conference on HIV Science (IAS ...
Biktarvy Continues to Show Safety and Efficacy Across Diverse Populations Impacted by the Global HIV Epidemic: Updated Findings from IAS 2023
Source – Gilead Gilead Sciences, has released the results of several studies further solidifying Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir ...
Gilead’s $8 Million Grant Funding for US Viral Hepatitis Relink Program
Source – Gilead FGilead Sciences, on July 20, has introduced the Gilead Relink program, a new grant initiative in the ...
Gilead’s IAS 2023: Advancing Health Equity and HIV Pipeline Progress
Source – Gilead On July 20, a leading force in HIV innovation, announced its significant participation in the 12th International ...
To increase treatment and adherence rates for children with HIV in low- and middle-income countries, Gilead collaborates with CHAI and Penta
Source – Gilead Sciences Gilead Sciences is pleased to announce two collaborative initiatives. The first initiative aims to expedite the ...
Gilead and Teva were acquitted in a $3.6 billion trial involving alleged ‘pay-for-delay’ schemes
Gilead Sciences and Teva have been exonerated by a California court jury in a lawsuit accusing them of colluding to ...
Kite Successfully Transfers Marketing Authorization for Yescarta CAR T-cell Therapy in Japan
Source – Gilead Sciences According to Kite Pharma on June 22, 2023, the marketing authorization for Yescarta, a chimeric antigen ...
